CMS sets Medicare price for Renalytix's kidneyintelX.dkd test at $950, effective Jan 2024

Renalytix plc

CMS published price for FDA-authorized kidneyintelX.dkd test on national Clinical Lab Fee Schedule at $950.
Pricing effective Jan 1, 2024 and maintained for a minimum of three years.
AMA panel recommended a new CPT code to differentiate kidneyintelX.dkd from the original LDT, triggering the pricing review.
Company states the CMS action affirms KidneyIntelX platform value and aids in expanding insurance coverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.